David R. Liu - Jun 30, 2025 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
10%+ Owner
Signature
/s/ Ryan Brown, attorney-in-fact
Stock symbol
PRME
Transactions as of
Jun 30, 2025
Transactions value $
$52,830
Form type
4
Date filed
7/1/2025, 04:03 PM
Previous filing
Jun 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Liu David R. 10%+ Owner C/O PRIME MEDICINE, INC., 60 FIRST STREET, CAMBRIDGE /s/ Ryan Brown, attorney-in-fact 2025-07-01 0001664439

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRME Common Stock Purchase $52.8K +21K +0.1% $2.52 20.2M Jun 30, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.
F2 The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.